The Russian pharmaceutical company R-Pharm, owned by Alexei Repik, plans to start production of the Russian Sputnik-V vaccine in Germany, although the vaccine has not yet been approved for use by the European Union, writes the Russian newspaper Kommersant, noting that the company took a three-year loan of 50 million euros from Raiffeisenbank to expand its facilities at its plant in the Bavarian town of Ilertisen.
The artleggia drug used to treat Covid-19 and the AstraZeneca vaccine, which R-Pharm already makes in Moscow but is intended for export, are currently being manufactured there. However, a number of sources cited by the Kommersant newspaper doubt that the company, which failed to organize a large-scale production of the Sputnik-V vaccine in Russia, will be able to do so abroad, not to mention, writes the newspaper on the unclear prospects of vaccine approval in Europe.
R-Pharm acquired the unit in Ilertisen from Pfizer in 2014. R-Pharm says it will produce up to 150 million doses a year of coronavirus vaccines and artleggia, but did not specify which vaccines they would produce before from the approval of Sputnik-V. Sputnik V will also be produced here for the local market once the Russian vaccine is approved by the European Medicines Agency (EMA), R-Pharm and Raiffeisenbank said.
SOURCE: AMPE
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
